Dynavax Technologies Corp.

Dr. Dina has been our President and a member of our Board of Directors since May 1997 and our Chief Executive Officer since May 1998. From 1982 until he joined us in 1997, Dr. Dina was an employee of Chiron Corporation, a biopharmaceutical company. At Chiron, Dr. Dina held a series of positions with increasing responsibility. He ultimately served as president of Chiron Vaccines (formerly Biocine Company), which he directed from its inception in 1987. Under Dr. Dina's direction, Chiron Vaccines received the first-ever approval of an adjuvanted influenza vaccine in Italy, successfully completed development of the first genetically engineered pertussis vaccine, and conducted clinical trials for vaccines to prevent HIV, herpes simplex type II, cytomegalovirus, and hepatitis B infections. The virology group he directed was responsible for several key scientific findings, including the discovery, cloning, and sequencing of the hepatitis C virus, and the cloning and sequencing of the viral genomes for HIV and hepatitis A viruses. Prior to joining Chiron, Dr. Dina was employed at Albert Einstein College of Medicine in Bronx, New York, as an assistant professor of genetics from 1977 to 1982. He received his M.D. from the University of Genova Medical School in Italy.

Dr. Janowicz joined Dynavax in April 2006 when Dynavax acquired Rhein Biotech GmbH (a Dynavax Europea ?). In July 2006 Dr. Janowicz was appointed CEO of Dynavax Europe. Dr. Janowicz holds a Ph.D. in Biochemistry. He was one of the co-founders of Rhein Biotech GmbH in 1985 and laid the foundation for the development and commercialization of the Hansenula polymorpha technology platform used in the production of vaccine antigens and other proteins.A He also led the successful development of the hepatitis B franchise of the Rhein Biotech GmbH group. From 1996 until 1999, Dr. Janowicz served as R&D Director in the tissue repair business of Curative Technologies. He rejoined Rhein Biotech GmbH in 1999 where he held the position of R&D Director for the Rhein Biotech Group.

Ms. Smeltzer joined Dynavax in January 2005 as Vice President, Operations and Chief Financial Officer, or CFO. Previously she was with Applied Biosystems, where she served most recently as Vice President and General Manager of the company's genetic analysis business. She previously served as Vice President, Finance for the organization and had responsibility for business development. Prior to Applied Biosystems, Ms. Smeltzer served as Chief Financial Officer and Vice President for Genset SA, a Paris-based global genomics company. From 1988 to 1996, Ms. Smeltzer was a general partner of the Grotech Capital Group venture funds where she managed the life sciences portfolio of the funds. Ms. Smeltzer serves on the board of directors and compensation committee of ExonHit Therapeutics, SA. She holds a BS in biological sciences and an MS in medical microbiology from the University of California, Irvine, and an MBA from Stanford University Graduate School of Business.

Dr. Martin is the Vice President and Chief Medical Officer and manages Dynavaxa s clinical affairs.A Dr. Martin has nearly 20 years of drug development experience.A Before joining Dynavax in 2009, Dr. Martin was President of Humabs LCC.A Previously, Dr. Martin worked at Chiron as the Vice President, Development from 2004 until 2006 and the Director, Clinical Research from 1994 until 1997.A In his 7 years at Chiron, Dr. Martin led the team responsible for the development of the novel vaccine adjuvant MF59, the first vaccine adjuvant licensed by regulatory agencies since alum, and approved as FLUAD influenza vaccine in Europe.A He has also held senior development and research positions at Sangamo, Inc., Valentis, Inc. and SyStemix/GTI.A Dr. Martin received a B.S. in Chemistry and an M.D. from the University of Nebraska.A He completed his fellowship in pediatric infectious diseases and molecular microbiology at Washington University in St. Louis, Missouri.

Mr. Ostrach joined Dynavax in October 2006 as Vice President, Chief Business Officer and General Counsel. Previously he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as general counsel and finally as Senior Vice President of corporate affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach became President of Chiron Technologies. He holds an AB from Brown University and a JD from Stanford Law School.

Dr. Coffman has been our Vice President and Chief Scientific Officer since December 2000. Dr. Coffman joined Dynavax from the DNAX Research Institute where he had been since 1981, most recently as Distinguished Research Fellow. Prior to that, he was a postdoctoral fellow at Stanford University Medical School. Dr. Coffman has made fundamental discoveries about the regulation of immune responses in allergic and infectious diseases. He shared the William S. Coley Award for Research in Immunology for discovery of the Th1 and Th2 subsets of T lymphocytes, the two major types of T cells that control most immune responses. Dr. Coffman received his Ph.D. from the University of California, San Diego and his AB from Indiana University. In 2006, Dr. Coffman was elected to the National Academy of Sciences.

Ms. Vitug has been our Vice President of Human Resources since October 2006. She previously served as Senior Director of Human Resources and Director of Human Resources since joining us in June 2000. From 1997 to 2000, Ms. Vitug was employed by Collagen Aesthetics, Inc., where she was Director of Human Resources, Payroll and Administrative Services. Ms. Vitug brings to Dynavax more than 20 years of human resources and administrative services experience, including positions at Somatix Therapy Corporation, Chiron Corporation, and Wells Fargo Bank.

Ms. Neptune joined Dynavax in January 2008 and serves as the Company's Vice President, Clinical Operations responsible for all clinical-stage development programs. Ms. Neptune has over 20 years of experience in clinical operations. Prior to joining Dynavax, Ms. Neptune was the Senior Director, Clinical Operations at ARYx Therapeutics from 2005 until 2008. She previously worked with Genentech as Associate Director, Clinical Affairs for Rituxan between 2003 and 2005. In addition, Ms. Neptune worked as Director, Clinical Development Operations for Onyx Pharmaceuticals between 2001 and 2003. She holds a BS in Kinesiology from the University of California, Los Angeles.

Dr. Guzman is Vice President, CMC Technologies at Dynavax responsible for CMC development, quality control, and supply of clinical trial materials.A He joined Dynavax in 2005 as Director, Technical Affairs.A Dr. Guzman has over 20 years of experience in scientific research.A Before joining Dynavax, between 1999 and 2005 Dr. Guzman worked for Pfizer, Inc. as Associate Research Fellow, Chemical Research and Development and as a Senior Scientist.A At Pfizer, Dr. Guzman was involved in the development of Macugena , an oligonucleotide-based treatment for age-related macular degeneration co-developed with Eyetech Pharmaceuticals as well as several small molecule development candidates targeting a variety of indications.A Between 1995 and 1998, Dr. Guzman worked at DuPont-Merck Pharmaceuticals in Chemical Research and Development.A Dr. Guzman received a Ph.D. from the University of Pennsylvania and a BS in Chemistry from the University of Illinois, Urbana-Champaign.

Mr. Turner came to Dynavax in August 2006 from Neosil, where he was Vice President, Regulatory Affairs. Bill was also a Senior Consultant with the Biologics Consulting Group and Senior Director of Regulatory Affairs with MedImmune Vaccines (formerly Aviron), and has worked with Allergan, Alpha Therapeutic Corporation, Watson Laboratories, and Gensia Laboratories. He has a BS in Medical Microbiology with a minor in Chemistry from California State University at Long Beach.

Dr. Oronsky has been a member of our Board of Directors since November 1996 and was elected Chairman in February 2006. Dr. Oronsky is a general partner with InterWest Partners, a venture capital firm. Prior to joining InterWest Partners in 1994, Dr. Oronsky was vice president of discovery research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at Johns Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky serves on the boards of directors of Aspreva Pharmaceuticals Corporation; Anesiva, Inc.; and Metabasis Therapeutics, Inc. He received his Ph.D. from Columbia University, College of Physicians and Surgeons, and his AB from New York University.

Dr. Lawrence was appointed to our Board in December 2006. Dr. Lawrence is the Retired Chairman and Chief Executive Officer of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals (KFHP/KFH). Dr. Lawrence currently serves on the Boards of Agilent Technologies, Raffles Medical Group of Singapore, McKesson Corporation, and the RAND Health Advisory Board, among others. He also serves in advisory roles to the biotechnology industry. He has been a consultant to Dynavax since May 2005. Dr. Lawrence joined Kaiser in 1981. He was named chief executive officer of KFHP/KFH in 1991 and chairman of its Board in 1992. Prior to that, he served as vice chairman and chief operating officer as well as a key executive in Kaiser Permanente divisions in Oregon and Colorado. He retired on December 31, 2002. Dr. Lawrence is a graduate of Amherst College (BA), the University of Kentucky (MD), and the University of Washington (MPH). He is Board Certified in General Preventive Medicine (the Johns Hopkins University and the University of Washington). He is a member of Alpha Omega Alpha (Medical Honorary Society) and the Institute of Medicine (National Academy of Sciences).

Dr. Lichtenstein is a recognized expert in the field of allergy and immunology. He is director of the Division of Clinical Immunology at Johns Hopkins University School of Medicine, and serves on the National Advisory Council, Allergy and Infectious Diseases of the National Institutes of Health (NIH). He has a long association with both institutions, initially joining the University staff in 1966 and serving various terms at the NIH since 1972. In addition, Dr. Lichtenstein has received a variety of honors and awards for his research, and has served on the editorial boards of a variety of publications including The Journal of Allergy and Clinical Immunology, The Journal of Immunology, and others. Dr. Lichtenstein received his M.D. from the University of Chicago and his Ph.D. in immunology from Johns Hopkins University.

Dr. Gilbert was appointed to our Board in March 2004. Dr. Gilbert is currently an independent consultant and strategic advisor to life science companies. From 2001 to 2002, she served as Chief Executive Officer of Entigen Corporation, a private life science information technology company. From 1995 to 1999, Dr. Gilbert served as Chief Financial Officer and Executive Vice President of Incyte Pharmaceuticals (now Incyte Corporation), and from 1993 to 1995 she was Chief Financial Officer and Executive Vice President of Affymax. From 1986 through 1993 Dr. Gilbert was a Managing Director and senior biotechnology analyst at Smith Barney Harris & Upham and Vice President and biotechnology analyst at Montgomery Securities. Dr. Gilbert serves on the board of Cytokinetics, Inc. and KaloBios Pharmaceuticals, Inc. Dr. Gilbert holds a B.S. from Cornell University and a Ph.D. in Cell and Developmental Biology from Harvard University.

Ms. Buc was appointed to our Board in November 2005. Ms. Buc is a partner in the Washington, D.C. law firm Buc & Beardsley, and has had a long and distinguished legal career with a strong focus on healthcare policy and government service. Ms. Buc formerly served as Chief Counsel for the U.S. Food and Drug Administration. During an earlier period of government service, she served successively as Attorney-Advisor to the Chairman of the Federal Trade Commission (FTC) and Assistant Director of the FTC s Bureau of Consumer Protection. Ms. Buc has served as a member of several major government panels, including the National Institutes of Health (NIH) Recombinant DNA Advisory Committee, the NIH Consensus Panel on Effective Medical Treatment of Heroin Addiction, and the Office of Technology Assessment s Advisory Panels on Government Policies and Pharmaceutical Research and Development, and New Developments in Biotechnology. She was also a member of the Institute of Medicine s committees on Contraceptive Research and Development and NIDA Medications Development. She was also the Chair of the Food and Drug Law Institute s Board of Directors. She received her Bachelor of Arts degree from Brown University and her Bachelor of Law degree from the University of Virginia, and was awarded an honorary doctor of laws degree from Brown University. She has served as both a trustee and a fellow on the Brown University Corporation, Brown s governing body. She has been a director of the National Partnership for Women and Families.

Dr. Carson has been a member of our Board since December 1997. Dr. Carson is a noted researcher in the fields of autoimmune and immunodeficiency diseases and is co-discoverer with Dr. Eyal Raz of the immunostimulatory sequences (ISS) that form the basis of our technology. He has played key roles in the founding of Vical, Inc., a gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals. Dr. Carson is director of the Rebecca and John Moores Cancer Center at the University of California, San Diego and has been a professor in the Department of Medicine at the University of California, San Diego since 1990. He is a member of the National Academy of Sciences, American Academy of Arts and Sciences, and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology, and the Association of American Physicians. He received his M.D. from Columbia University and his B.A. from Haverford College. Dr. Carson completed his residency in internal medicine and a postdoctoral fellowship at the University of California San Diego.

Dr. Raz is an immunologist whose research on immunostimulatory DNA sequences forms the basis of Dynavax's technology platform. Dr. Raz has been an associate professor of medicine at the University of California, San Diego since 1996, and an assistant research immunologist at that institution since 1993. Prior to that time, he was employed at Hadassah University Hospital in Jerusalem, Israel as assistant professor of medicine in 1989 and senior physician, Department of Medicine in 1988. He received his M.D. degree from the Hebrew University, Hadassah Medical School in Jerusalem, Israel.

Dr. Bartelsen holds a Ph.D. in biochemistry. He joined Rhein Biotech GmbH in 1999 as a project leader of a network-program for the development of alternative industrial expression systems. Simultaneously, he managed the acquisition of contract services and licensing-in of technology platforms. In 2002 and 2003, Dr. Bartelsen was International Project Manager for the development and registration of a EU-GMP compliant thiomersal-free hepatitis B vaccine. During 2004 his activities included the responsibility for global business development industrialization within the Berna Group. In September 2004, Dr. Bartelsen assumed responsibility for business development, industrialization and project management at Rhein Biotech GmbH.

Ms. Phillips was appointed to our Board in August 2006. Ms. Phillips currently also serves on the boards of directors of Portola Pharmaceuticals and the United States Naval Academy Foundation and she served on the board of Western Wireless from 2004 until the acquisition by Alltel in mid-2005. From 1996 until 2002, she served on the board of directors of Immunex Corporation and from 1999 she served as the Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As senior vice president for pharmaceutical development and general manager for Enbrel , she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories. Ms. Phillips holds a BS and a MS in microbiology from the University of Idaho.

Dr. Stanley Plotkin joined our Board of Directors in August 2005. Dr. Plotkin is Emeritus Professor of the University of Pennsylvania and Executive Advisor to Sanofi Pasteur. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, and Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught (today, Sanofi Pasteur), where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. Dr. Plotkin’s career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin received the Bruce Medal in Preventive Medicine of the American College of Physicians, the Distinguished Physician Award of the Pediatric Infectious Diseases Society and the Clinical Virology Award of the Pan American Society for Clinical Virology. In June 1998, he received the French Legion of Honor Medal, in June 2001, the Distinguished Alumnus Award of the Children’s Hospital of Philadelphia, the Sabin Gold Medal in May 2002, and in September 2004 the Bristol Award of the Infectious Diseases Society of America. A lecture in his honor has been established at the Pediatric Academic Societies annual meeting. His bibliography includes over 600 articles and he has edited several books including the standard textbook on vaccines, now in its fourth edition.